Duffy antigen system

Duffy antigen system

Atypical chemokine receptor 1 (Duffy blood group)
Available structures
PDB Ortholog search: PDBe, RCSB
Identifiers
Symbols  ; CCBP1; CD234; DARC; Dfy; FY; GPD; GpFy; WBCQ1
External IDs IUPHAR: GeneCards:
Orthologs
Species Human Mouse
Entrez
Ensembl
UniProt
RefSeq (mRNA)
RefSeq (protein)
Location (UCSC)
PubMed search

Duffy antigen/chemokine receptor (DARC), also known as Fy glycoprotein (FY) or CD234 (Cluster of Differentiation 234), is a protein that in humans is encoded by the DARC gene.[1][2][3]

The Duffy antigen is located on the surface of red blood cells, and is named after the patient in which it was discovered. The protein encoded by this gene is a glycosylated membrane protein and a non-specific receptor for several chemokines. The protein is also the receptor for the human malarial parasites Plasmodium vivax and Plasmodium knowlesi. Polymorphisms in this gene are the basis of the Duffy blood group system.[4]

Contents

  • History 1
  • Genetics and genomics 2
  • Molecular biology 3
  • Population genetics 4
  • Clinical significance 5
    • Asthma 5.1
    • Benign ethnic neutropenia 5.2
    • Cancer 5.3
    • Endotoxin response 5.4
    • HIV infection 5.5
    • Inflammation 5.6
    • Lung transplantation 5.7
    • Malaria 5.8
    • Multiple myeloma 5.9
    • Pneumonia 5.10
    • Pregnancy 5.11
    • Prostate cancer 5.12
    • Renal transplantion 5.13
    • Sickle cell anaemia 5.14
    • Southeast Asian ovalocytosis 5.15
    • Transfusion medicine 5.16
  • Transfusion data 6
    • Antibody Type 6.1
    • Antibody Behavior 6.2
    • Transfusion reactions 6.3
    • Hemolytic disease of the fetus and newborn (HDFN) 6.4
  • References 7
  • Further reading 8
  • External links 9

History

It was noted in the 1920s that black Africans had some intrinsic resistance to infection with malaria, but the basis for this remained unknown. The Duffy antigen gene was the fourth gene associated with the resistance after the genes responsible for sickle cell anaemia, thalassemia and glucose-6-phosphate dehydrogenase.

In 1950, the Duffy antigen was discovered in a multiply-transfused hemophiliac whose serum contained the first example of anti-Fya antibody.[5] In 1951, the antibody to a second antigen, Fyb, was discovered in serum. Using these two antibodies, three common phenotypes were defined: Fy(a+b+), Fy(a+b-), and Fy(a-b+).

Several other types were later discovered bringing the current total up to 6: Fya, Fyb, Fy3, Fy4, Fy5 and Fy6. Only Fya, Fyb and Fy3 are considered clinically important. Reactions to Fy5 have also rarely been reported.

Genetics and genomics

The Duffy antigen /chemokine receptor gene (gp-Fy; CD234) is located on the long arm of chromosome 1 (1.q22-1.q23) and was cloned in 1993.[2] The gene was first localised to chromosome 1 in 1968 and was the first blood system antigen to be localised. It is a single copy gene spanning over 1500 bases and is in two exons. It encodes a 336 amino acid acidic glycoprotein. The gene carries the antigenic determinants of the Duffy blood group system which consist of four codominant alleles—FY*A and FY*B—coding for the Fy-a and Fy-b antigens respectively, FY*X and FY*Fy, five phenotypes (Fy-a, Fy-b, Fy-o, Fy-x and Fy-y) and five antigens. Fy-x is a form of Fy-b where the Fy-b gene is poorly expressed. Fy-x is also known as Fy-bweak or Fy-bWk.

Fy-a and Fy-b differ by in a single amino acid at position 42: glycine in Fy-a and aspartic acid in Fy-b (guanine in Fy-a and adenosine in Fy-b at position 125). A second mutation causing a Duffy negative phenotype is known: the responsible mutation is G -> A at position 298. The genetic basis for the Fy(a-b-) phenotype is a point mutation in the erythroid specific promoter (a T -> C mutation at position -33 in the GATA box).[6] This mutation occurs in the Fy-b allele and has been designated Fy-bEs (erythroid silent). Two isotypes have been identified. The Fy-x allele is characterized by a weak anti-Fy-b reaction and appears to be the result of two separate transitions: Cytosine265Threonine (Arginine89Cysteine) and Guanine298Adenosine (Alanine100Threonine). A third mutation (a transversion) in this gene has also been described - G145T (Alanine49Serine) - that has been associated with the Fy-x phenotype.

Most Duffy negative blacks carry a silent Fy-b allele with a single T to C substitution at nucleotide -46, impairing the promoter activity in erythroid cells by disrupting a binding site for the GATA1 erythroid transcription factor. The gene is still transcribed in non erythroid cells in the presence of this mutation.

The Duffy negative phenotype occurs at low frequency among whites (~3.5%) and is due to a third mutation that results in an unstable protein (Arg89Cys: cytosine -> thymidine at position 265).[7]

The silent allele has evolved at least twice in the black population of Africa and evidence for selection for this allele has been found.[8] The selection pressure involved here appears to be more complex than many text books might suggest.[9] An independent evolution of this phenotype occurred in Papua New Guinea has also been documented.[10]

A comparative study of this gene in seven mammalian species revealed significant differences between species.[11] The species examined included Pan troglodytes (chimpanzee), Macaca mulatta (rhesus monkey), Pongo pygmaeus (orangutan), Rattus norvegicus (brown rat), Mus musculus (mouse), Monodelphis domestica (opossum), Bos taurus (cow) and Canis familiaris (dog).

Three exons are present in humans and chimpanzees while only two exons occur in the other species. This additional exon is located at the 5' end and is entirely non coding. Both intron and exon size vary considerably between the species examined. Between the chimpanzee and the human 24 differences in the nucleotide sequence were noted. Of these 18 occurred in non coding regions. Of the remaining 6, 3 were synonymous and 3 non synonymous mutations. The significance of these mutations if any is not known.

The mouse ortholog has been cloned and exhibits 63% homology to the human gene at the amino acid level. The mouse gene is located on chromosome 1 between the genetic markers Xmv41 and D1Mit166. The mouse gene has two exons (100 and 1064 nucleotides in length respectively), separated by a 461 base pair intron. In the mouse DARC is expressed during embryonic development between days 9.5 and 12.

In yellow baboons (Papio cynocephalus) mutations in this gene have been associated with protection from infection with species of the genus Hepatocystis.[12]

The ancestral form of extant DARC alleles in humans appears to be the FY*B allele.[13]

The gene appears to be under strong purifying selection.[14] The cause of this selective pressure has not yet been identified.

Molecular biology

Biochemical analysis of the Duffy antigen has shown that it has a high content of α-helical secondary structure - typical of chemokine receptors.[15] Its N-glycans are mostly of the triantennary complex type terminated with α2-3- and α2-6-linked sialic acid residues with bisecting GlcNAc and α1-6-linked fucose at the core.

The Duffy antigen is expressed in greater quantities on

  • DARC protein, human at the US National Library of Medicine Medical Subject Headings (MeSH)
  • Duffy at BGMUT Blood Group Antigen Gene Mutation Database at NCBI, NIH
  • Duffy gene
  • Population data

External links

Further reading

  1. ^
  2. ^ a b
  3. ^
  4. ^
  5. ^
  6. ^ Tournamille C, Colin Y, Cartron JP, Le Van Kim C. Disruption of a GATA motif in the Duffy gene promoter abolishes erythroid gene expression in Duffy-negative individuals. Nat Genet. 1995 Jun;10(2):224–8
  7. ^
  8. ^ a b
  9. ^
  10. ^
  11. ^
  12. ^
  13. ^ Schmid P, Ravenell KR, Sheldon SL, Flegel WA (2011) DARC alleles and Duffy phenotypes in African Americans. Transfusion doi:10.1111/j.1537-2995.2011.03431.x.
  14. ^
  15. ^
  16. ^ a b
  17. ^
  18. ^
  19. ^
  20. ^
  21. ^
  22. ^
  23. ^
  24. ^
  25. ^
  26. ^
  27. ^ a b
  28. ^
  29. ^
  30. ^
  31. ^
  32. ^
  33. ^
  34. ^
  35. ^
  36. ^
  37. ^
  38. ^
  39. ^
  40. ^
  41. ^ a b
  42. ^
  43. ^
  44. ^
  45. ^
  46. ^
  47. ^
  48. ^
  49. ^
  50. ^
  51. ^
  52. ^
  53. ^
  54. ^
  55. ^
  56. ^
  57. ^
  58. ^
  59. ^
  60. ^
  61. ^
  62. ^ a b
  63. ^
  64. ^
  65. ^
  66. ^
  67. ^ a b c
  68. ^
  69. ^
  70. ^
  71. ^
  72. ^
  73. ^
  74. ^
  75. ^
  76. ^
  77. ^
  78. ^
  79. ^
  80. ^
  81. ^
  82. ^
  83. ^
  84. ^
  85. ^
  86. ^
  87. ^ a b c Roback JD et al. AABB Technical Manual, 16th Ed. Bethesda: AABB Press, 2008.
  88. ^ Klein HG, Anstee DJ. Mollison's Blood Transfusion in Clinical Medicine. 11th Ed. Oxford: Blackwell Publishing, 2005.

References

Hemolytic disease of the fetus and newborn is typically mild but rarely may be serious. Almost always due to anti-Fya and rarely anti-Fyb or Fy3.

Hemolytic disease of the fetus and newborn (HDFN)

Typically mild but may be serious, even fatal. Although these usually occur immediately they may occur after a delay (up to 24 hours). These reactions are usually caused by anti-Fya or anti-Fyb. anti-Fy3 may cause acute or delayed hemolytic transfusion reactions (HTRs), but only rarely.
Anti-Fy5 may also cause delayed hemolytic transfusion reactions.[87]

Transfusion reactions

Anti-Fya is a common antibody while anti-Fyb is approximately 20 times less common.,[87][88] They are reactive at body temperature and are therefore clinically significant, although they do not typically bind complement. Antibodies are acquired through exposure (pregnancy or history of blood transfusion) and subsequent alloimmunization. They display dosage (react more strongly to homozygous cells versus heterozygous cells).[87]

Antibody Behavior

Almost entirely IgG. IgG1 usually predominates. IgM does occur but is rare.

Antibody Type

Number of Duffy antigens: 6

Gene name: Duffy blood group

Gene symbol: FY

ISBT number: 008

International Society for Blood Transfusion (ISBT) symbol: FY

Transfusion data

A Duffy negative blood recipient may have a transfusion reaction if the donor is Duffy positive.[41] Since most Duffy-negative people are of African descent, blood donations from people of black African origin are important to transfusion banks.

Transfusion medicine

There is a ~10% increase in Fy expression in Southeast Asian ovalocytosis erythocytes.[86]

Southeast Asian ovalocytosis

[85] Duffy-positive patients exhibit higher counts of white blood cells, polynuclear neutrophils, higher plasma levels of IL-8 and RANTES than Duffy-negative patients.[84] Duffy antigen-negative individuals with

Sickle cell anaemia

Antibodies and a cellular response to the Duffy antigen have been associated with renal transplant rejection.[83]

Renal transplantion

Experimental work has suggested that DARC expression inhibits prostate tumor growth. Men of black African descent are at greater risk of prostate cancer than are men of either Causcasian or Asian descendant (60% greater incidence and double the mortality compared to Caucasians). The reasons for this increased risk are not known. The contribution of DARC to this increased risk has been tested in Jamaican males of black African descent.[82] It was found that none of the increased risk could be attributed to the DARC gene.

Prostate cancer

Duffy antigen has been implicated in haemolytic disease of the newborn.

Pregnancy

The Duffy antigen is present in the normal pulmonary vascular bed. Its expression is increased in the vascular beds and alveolar septa of the lung parenchyma during suppurative pneumonia.[27]

Pneumonia

An increased incidence of Duffy antigen has been reported in patients with multiple myeloma compared with healthy controls.[81]

Multiple myeloma

The Duffy antigen binding protein in P. vivax is composed of three subdomains and is thought to function as a dimer.[80] The critical DARC binding residues are concentrated at the dimer interface and along a relatively flat surface spanning portions of two subdomains.

The binding of platelet factor 4 (CXCL4) appears to be critical for the platelet induced killing of P. falciparum.[79]

A difference between the susceptibility to Plasmodium vivax malaria has been reported.[78] Erythrocytes expressing Fya had 41-50% lower binding of P. vivax compared with Fyb cells. Individuals with the Fy(a+b-) phenotype have a 30-80% reduced risk of clinical vivax but not falciparum malaria.

Examination of this gene in 497 patients in the Amazonas State, Brazil, made by the doctor Sérgio Albuquerque, suggests that the genotypes FY*A/FY*B-33 and FY*B/FY*B-33 (where -33 refers to the null mutation at position -33 in the GATA box) may have an advantage over the genotypes FY*A/FY*B and FY*A/FY*A, FY*A/FY*B, FY*A/FY*X and FY*B/FY*X.[77] FY*A/FY*B and FY*A/FY*A genotypes showed to be associated with increased rates of P. vivax infection and FY*B/FY*X and FY*A/FY*X were shown to be associated with the low levels of parasitism.

Nancy Ma's night monkey (A. nancymaae) is used as an animal model of P. vivax infection. This species' erythrocytes possess the Duffy antigen and this antigen is used as the receptor for P. vivax on the erythrocytes in this species.[76]

The protection to P. vivax malaria conferred by the absence of the Duffy antigen appears to be very limited at best in Madagascar. Although 72% of the population are Duffy antigen negative, 8.8% of the Duffy antigen negative individuals were asymptomatic carriers of P. vivax.[68] Malaria has also been found in Angola and Equatorial Guinea in Duffy negative individuals.[69] P. vivax malaria in a Duffy antigen negative individual in Mauritania has also been reported.[70] Similar infections have been reported in Brazil[71][72] and Kenya.[67] Additional cases of infection in Duffy antigen negative individuals have been reported from the Congo[73] and Uganda.[74] A study in Brazil of the protection against P. vivax offered by the lack of the Duffy antigen found no differential resistance to malaria vivax between Duffy antigen positive and negative individuals.[75]

On erythrocytes, the Duffy antigen acts as a receptor for invasion by the human malarial parasites P. vivax and P. knowlesi. This was first shown in 1980. Duffy negative individuals whose erythrocytes do not express the receptor are believed to be resistant to merozoite invasion[67] although P. vivax infection has been reported in Duffy negative children in Kenya, suggesting a role in resistance to disease, not infection.[67] This antigen may also play a role in erythrocyte invasion in the rodent malarial parasite P. yoelii. The epitope Fy6 is required for P. vivax invasion.[16]

Malaria

The Duffy antigen has been implicated in lung transplantation rejection.[66]

Lung transplantation

An association with the levels monocyte chemoattractant protein-1 has been reported.[65]

Inflammation

A study of 142 black South African high-risk female sex workers over 2 years revealed a seroconversion rate of 19.0%.[64] Risk of seroconversion appeared to be correlated with Duffy-null-associated low neutrophil counts.

The association between the Duffy antigen and HIV infection appears to be complex. Leukopenia (a low total white cell count) is associated with relatively poor survival in HIV infection and this association is more marked in caucasians than in people of Black African descent, despite the (on average) lower white cell counts found in black Africans. This difference appears to correlate with a particular genotype (-46C/C) associated with the absence of the Duffy antigen.[63] This genotype has only been found in black Africans and their descendants. The strength of this association increases inversely with the total white cell count. The basis for this association is probably related to the role of the Duffy antigen in cytokine binding but this has yet to be verified.

HIV-1 appears to be able to attach to erythrocytes via DARC.[62]

A connection has been found between HIV susceptibility and the expression of the Duffy antigen. The absence of the DARC receptor appears to increase the susceptibility to infection by HIV. However once established, the absence of the DARC receptor appears to slow down the progression of the disease.[62]

HIV infection

The procoagulant response to lipopolysaccaride (bacterial endotoxin) is reduced in Duffy antigen negative Africans compared with Duffy positive Caucasians.[61] This erence is likely to involve additional genes.

Endotoxin response

Interactions between the metastasis suppressor KAI1 on tumor cells and the cytokine receptor DARC on adjacent vascular cells suppresses tumor metastasis.[59] In human breast cancer samples low expression of the DARC protein is significantly associated with estrogen receptor status, both lymph node and distant metastasis and poor survival.[60]

Cancer

A significant proportion (25–50%) of otherwise healthy African Americans are known to have a persistently lower white blood cell count than the normal range defined for individuals of European ancestry—a condition known as benign ethnic neutropenia. This condition is also found in Arab Jordanians, Black Bedouin, Falashah Jews, Yemenite Jews and West Indians. This condition is associated with a reduced capacity to mobilize bone marrow neutrophil reserves in response to corticosteroids, despite normal cellularity and maturation of all cell lines in bone marrow aspirates. Strongly suggestive evidence has been found that links condition to a mutation in the Duffy gene.[58] Although the mechanism is as yet unknown, it is known that neutrophils are retained in the bone marrow through interaction of CXCL12 with its receptor CXCR4. A number of rare diseases are known in which disruption or desensitization of CXCR4 results in failure to release mature neutrophils from bone marrow.

Benign ethnic neutropenia

Asthma is more common and tends to be more severe in those of African descent. There appears to be a correlation with both total IgE levels and asthma and mutations in the Duffy antigen.[57]

Asthma

Historically the role of this antigen other than its importance as a receptor for Plasmodium protozoa has not been appreciated. Recent work has identified a number of additional roles for this protein.

Clinical significance

The distribution within India has been studied in some detail.[56]

There appears to have been a selective sweep in Africa which reduced the incidence of this antigen there. This sweep appears to have occurred between 6,500 and 97,200 years ago (95% confidence interval)[8]

  • The mutation Ala100Thr (G -> A in the first codon position—base number 298) within the FY*B allele was thought to be purely a Caucasian genotype, but has since been described in Brazilians. However, the study's authors point out that the Brazilian population has arisen from intermarriage between Portuguese, Black Africans, and Indians, which accounts for the presence of this mutation in a few members of Brazil's non-Caucasian groups. Two of the three Afro-Brazilian test subjects that were found to have the mutation (out of a total of 25 Afro-Brazilians tested) were also related to one another, as one was a mother and the other her daughter.[43]
  • This antigen along with other blood group antigens was used to identify the Basque people as a genetically separate group.[44] Its use in forensic science is under consideration.[45]
  • The Andaman and Nicobar Islands, now part of India, were originally inhabited by 14 aboriginal tribes. Several of these have gone extinct. One surviving tribe—the Jarawas—live in three jungle areas of South Andaman and one jungle area in Middle Andaman. The area is endemic for malaria. The causative species is Plasmodium falciparum: there is no evidence for the presence of Plasmodium vivax. Blood grouping revealed an absence of both Fy(a) and Fy(b) antigens in two areas and a low prevalence in two others.[46]
  • In the Yemenite Jews the frequency of the Fy allele is 0.5879[47] The frequency of this allele varies from 0.1083 to 0.2191 among Jews from the Middle East, North Africa and Southern Europe. The incidence of Fya among Ashkenazi Jews is 0.44 and among the non-Ashkenazi Jews it is 0.33. The incidence of Fyb is higher in both groups with frequencies of 0.53 and 0.64 respectively.[48]
  • In the Chinese ethnic populations—the Han and the She people—the frequencies of Fya and Fyb alleles were 0.94 and 0.06 and 0.98 and 0.02 respectively.[49]
  • The frequency of the Fya allele in most Asian populations is ~95%.
  • In Grande Comore (also known as Ngazidja) the frequency of the Fy(a- b-) phenotype is 0.86.[50]
  • In a survey of 115 unrelated Tunisians using both serological and DNA based methods gave the following results: FY*X frequency 0.0174; FY*1 = 0.291 (expressed 0.260, silent 0.031); FY*2 = 0.709 (expressed 0.427; silent 0.282). FY*2 silent is the most common allele in West African blacks and the high prevalence in this sample was interpreted as historical admixture.[51]
  • The incidence of Fy(a+b-) in northern India among blood donors is 43.85%.[52]
  • In Nouakchott, Mauritania overall 27% of the population are Duffy-positive. 54% of Moors are Duffy antigen positive, while only 2% of black ethnic groups (mainly Poular, Soninke and Wolof) are Duffy positive.[53]
  • A map of the Duffy antigen distribution has been produced.[54] The most prevalent allele globally is FY*A. Across sub-Saharan Africa the predominant allele is the silent FY*BES variant.
  • In Iran the Fy (a-b-) phenotype was found in 3.4%.[55]

While a possible role in the protection of humans from malaria had been previously suggested, this was only confirmed clinically in 1976.[42] Since then many surveys have been carried out to elucidate the prevalence of Duffy antigen alleles in different populations including:

  • Fy(a+b+): 49% Caucasians, 1% Blacks, 9% Chinese
  • Fy(a-b+): 34% Caucasians, 22% Blacks, <1% Chinese
  • Fy(a+b-): 17% Caucasians, 9% Blacks, 91% Chinese

Overall the frequencies of Fya and Fyb antigens in Caucasians are 66% and 83% respectively, in Asians 99% and 18.5% respectively and in blacks 10% and 23% respectively. The frequency of Fy3 is 100% Caucasians, 99.9% Asians and 32% Blacks. Phenotype frequencies are:

Differences in the racial distribution of the Duffy antigens were discovered in 1954, when it was found that the overwhelming majority of blacks had the erythrocyte phenotype Fy(a-b-): 68% in African Americans and 88-100% in African blacks (including more than 90% of West African blacks).[40] This phenotype is exceedingly rare in Caucasians. Because the Duffy antigen is uncommon in those of Black African descent, the presence of this antigen has been used to detect genetic admixture. In a sample of unrelated African Americans (n = 235), Afro-Caribbeans (n = 90) and Colombians (n = 93), the frequency of the -46T (Duffy positive) allele was 21.7%, 12.2% and 74.7% respectively.[41]

Population genetics

Binding melanoma growth-stimulating activity inhibits the binding of P. knowlesi to DARC.

DARC has been shown to internalise chemokines but does not scavenge them.[39] It mediates chemokine transcytosis, which leds to apical retention of intact chemokines and more leukocyte migration.

The Duffy antigen has been shown to exist as a constitutive homo-oligomer and that it hetero-oligomerizes with the CC chemokine receptor CCR5 (CD195). The formation of this heterodimer impairs chemotaxis and calcium flux through CCR5, whereas internalization of CCR5 in response to ligand binding remains unchanged.[38]

The protein is also known to interact with the protein KAI1 (CD82) a surface glycoprotein of leukocytes and may have a role in the control of cancer.

In DARC-transfected cells, DARC is internalized following ligand binding and this led to the hypothesis that expression of DARC on the surface of erythrocytes, endothelial, neuronal cells and epithelial cells may act as a sponge and provide a mechanism by which inflammatory chemokines may be removed from circulation as well as their concentration modified in the local environment.[26] This hypothesis has also been questioned after knock out mice were created. These animals appeared healthy and had normal responses to infection. While the function of the Duffy antigen remains presently (2006) unknown, evidence is accumulating that suggests a role in neutrophil migration from the blood into the tissues[27] and in modulating the inflammatory response.[28][29][30][31][32][33][34][35][36][37]

Scatchard analysis of competition binding studies has shown high affinity binding to the Duffy antigen with dissociation constants (KD) binding values of 24 ± 4.9, 20 ± 4.7, 41.9 ± 12.8, and 33.9 ± 7 nanoMoles for MGSA, interleukin-8, RANTES and monocyte chemotactic peptide-1 respectively.[25]

Consequently, the Fy protein is also known as DARC (Duffy Antigen Receptor for Chemokines). The chemokine binding site on the receptor appears to be localised to the amino terminus.[24] The antigen is predicted to have 7 transmembrane domains, an exocellular N-terminal domain and an endocellular C-terminal domain. Alignment with other seven transmembrane G-protein-coupled receptors shows that DARC lacks the highly conserved DRY motif in the second intracellular loop of the protein that is known to be associated with G-protein signaling. Consistent with this finding ligand binding by DARC does not induce G-protein coupled signal transduction nor a Ca2+ flux unlike other chemokine receptors. Based on these alignments the Duffy antigen is considered to be most similar to the interleukin-8B receptors.

  • Growth related gene alpha (GRO-α) - CXCL1
  • Platelet factor 4 - CXCL4[23]
  • ENA-78 - CXCL5
  • Neutrophil activating peptide-2 (NAP-2) - CXCL7
  • Interleukin-8 (IL-8) - CXCL8

and the angiogenic CXC chemokines:

  • monocyte chemotatic protein-1 (MCP-1) - CCL2[20]
  • regulated upon activation normal T expressed and secreted (RANTES) - CCL5[21]
  • melanoma growth stimulatory activity (MSGA-α), KC, neutrophil-activating protein 3 (NAP-3) - CXCL1/CXCL2[22]

The Duffy antigen has been found to act as a multispecific receptor for chemokines of both the C-C and C-X-C families, including:

(Asn) 16 and Asn27. asparagine It has two potential N-linked glycosylation sites at [19] and the large pulmonary venules. In some people who lack the Duffy antigen on their erythrocytes it may still be expressed in some cells.[18]